NR565 Week 4 Midterm Exam Review Examplify
Online Proctored Exam For August 2nd 2026
Complete 100 Actual exam Questions and
Answer,s NR-565 Advanced Pharmacology
Fundamentals | 100% Pass Guaranteed | Graded
A+
1. A 72-year-old patient with a history of heart failure (ejection fraction 30%)
and chronic kidney disease (estimated CrCl 25 mL/min) is admitted with
pneumonia. The team considers gentamicin for gram-negative coverage. Which
of the following pharmacokinetic parameters is MOST critical to calculate for
safe and effective dosing in this patient?
A. Bioavailability (F)
B. Volume of Distribution (Vd)
C. Half-life (t½)
D. Protein Binding Percentage
Rationale: - answer-; C. Half-life (t½). In patients with significantly impaired renal
function, the half-life of renally excreted drugs like aminoglycosides (gentamicin)
is dramatically prolonged. Calculating the estimated half-life based on creatinine
clearance is essential to determine the dosing interval and prevent toxic
accumulation. While Vd (B) is used to calculate the loading dose, and protein
binding (D) can affect interactions, the critically altered parameter in renal failure
is the elimination half-life, which directly dictates the dosing frequency to avoid
,toxicity (nephrotoxicity, ototoxicity). Bioavailability (A) is less relevant for
intravenous dosing.
2. A patient stabilized on warfarin for atrial fibrillation begins taking phenytoin
for new-onset seizures. One week later, the patient's INR is subtherapeutic.
What is the MOST likely mechanism for this drug-drug interaction?
A. Phenytoin displaces warfarin from plasma protein binding sites.
B. Phenytoin inhibits the CYP2C9 metabolism of warfarin.
C. Phenytoin induces the CYP2C9 and CYP3A4 metabolism of warfarin.
D. Phenytoin reduces the absorption of warfarin in the GI tract.
Rationale: - answer-; C. Phenytoin induces the CYP2C9 and CYP3A4 metabolism
of warfarin. Phenytoin is a potent inducer of hepatic cytochrome P450 enzymes,
including CYP2C9 (the primary metabolizer of S-warfarin) and CYP3A4. This
increased enzymatic activity accelerates the metabolism and clearance of
warfarin, leading to a decreased anticoagulant effect and a subtherapeutic INR.
Answer A describes a protein-binding displacement interaction, which causes a
transient, sharp increase in free drug, not a sustained decrease. Answer B
describes an inhibitor, which would increase the INR. Answer D is not a
recognized significant interaction for these drugs.
Topic: Endocrine Pharmacology
3. A 55-year-old patient with Type 2 diabetes, hypertension, and established
atherosclerotic cardiovascular disease (ASCVD) presents with an A1C of 8.5% on
metformin 1000 mg BID. According to the current ADA/EASD consensus
guidelines, which of the following would be the MOST appropriate next
pharmacologic agent to add?
A. Glipizide (a sulfonylurea)
B. Sitagliptin (a DPP-4 inhibitor)
C. Empagliflozin (an SGLT2 inhibitor)
D. Pioglitazone (a thiazolidinedione)
Rationale: - answer-; C. Empagliflozin (an SGLT2 inhibitor). For patients with
Type 2 diabetes and established ASCVD (or heart failure, or CKD), the guidelines
strongly recommend an agent with proven cardiovascular benefit, such as an
SGLT2 inhibitor (empagliflozin, canagliflozin) or a GLP-1 receptor agonist with
proven benefit. Empagliflozin has robust data showing reduction in major adverse
,cardiovascular events (MACE) and hospitalization for heart failure. While all
options lower glucose, sulfonylureas (A) and DPP-4 inhibitors (B) are generally
considered glucose-centric with neutral CV effects. Pioglitazone (D) can increase
heart failure risk and is not a first-choice add-on in this specific clinical scenario.
4. A patient with primary hypothyroidism has been on a stable dose of
levothyroxine 112 mcg daily for one year with normal TSH. She now reports
starting calcium carbonate tablets for osteoporosis prevention. What is the
MOST appropriate clinical action?
A. Increase the levothyroxine dose by 25 mcg daily.
B. Check a TSH level in 6-8 weeks and counsel to separate administration times.
C. Switch to liothyronine (T3) therapy due to malabsorption.
D. No action is needed; there is no interaction.
Rationale: - answer-; B. Check a TSH level in 6-8 weeks and counsel to separate
administration times. Calcium carbonate (and other cations like iron, aluminum)
can bind to levothyroxine in the gut, significantly reducing its absorption. The
appropriate management is to instruct the patient to take levothyroxine on an
empty stomach (ideally 60 minutes before breakfast) and to take calcium
supplements (and other multivitamins) at a different time, such as with lunch or
dinner. A follow-up TSH is then required to ensure the patient's thyroid status
remains stable. Increasing the dose (A) preemptively is not appropriate. Switching
to T3 (C) is not standard management for this common interaction.
Topic: Cardiovascular & Renal Pharmacology
5. A 70-year-old man with heart failure with reduced ejection fraction (HFrEF, EF
28%), hypertension, and stage 3b CKD is on optimal therapy including lisinopril,
carvedilol, and furosemide. Despite this, he has persistent NYHA Class II
symptoms. Which of the following add-on therapies has been shown to reduce
cardiovascular mortality and HF hospitalizations in this population and is
appropriate given his renal function?
A. Digoxin
B. Hydralazine/isosorbide dinitrate
C. Spironolactone
D. Ivabradine
, Rationale: - answer-; C. Spironolactone (or its alternative eplerenone). In patients
with HFrEF (EF ≤35%) who remain symptomatic (NYHA Class II-IV) on an ACE-
I/ARB/ARNI and a beta-blocker, the addition of a mineralocorticoid receptor
antagonist (MRA) like spironolactone is a Class I recommendation based on the
RALES trial, showing significant reductions in mortality and hospitalization. It
requires monitoring of potassium and renal function but can be used with caution
in CKD. Digoxin (A) reduces hospitalizations but not mortality. Hydralazine/ISDN
(B) is specifically recommended for African American patients on optimal therapy.
Ivabradine (D) is for patients in sinus rhythm with a heart rate ≥70 bpm on max
beta-blocker therapy, and its benefit in concomitant significant CKD is less
defined.
Topic: Neurology/Psychiatry Pharmacology
6. A 45-year-old woman is diagnosed with major depressive disorder. She is
started on sertraline 50 mg daily. At her 2-week follow-up, she reports feeling
more anxious and having trouble sleeping. Her physical exam is normal. What is
the MOST appropriate next step?
A. Immediately discontinue sertraline due to risk of serotonin syndrome.
B. Add a benzodiazepine, such as lorazepam, for anxiety and insomnia.
C. Reassure the patient that these are common initial side effects and encourage
her to continue the medication.
D. Switch to a different antidepressant class, such as bupropion.
Rationale: - answer-; C. Reassure the patient that these are common initial side
effects and encourage her to continue the medication. Activation symptoms
(increased anxiety, agitation, insomnia) are a well-known, typically transient side
effect during the initial 1-3 weeks of SSRI therapy. The appropriate management
is education, reassurance, and support to persist, as the therapeutic
antidepressant effect often takes 4-8 weeks. Discontinuation (A) is premature.
Adding a benzodiazepine (B) may create a new problem of dependence and is not
first-line. Switching (D) may be considered if side effects are intolerable or persist,
but it is too early in treatment to make that decision.
7. A 28-year-old patient with moderate persistent asthma is prescribed a
combination inhaled corticosteroid/long-acting beta-agonist (ICS/LABA). The
patient uses a short-acting beta-agonist (SABA) albuterol inhaler 3-4 times per
Online Proctored Exam For August 2nd 2026
Complete 100 Actual exam Questions and
Answer,s NR-565 Advanced Pharmacology
Fundamentals | 100% Pass Guaranteed | Graded
A+
1. A 72-year-old patient with a history of heart failure (ejection fraction 30%)
and chronic kidney disease (estimated CrCl 25 mL/min) is admitted with
pneumonia. The team considers gentamicin for gram-negative coverage. Which
of the following pharmacokinetic parameters is MOST critical to calculate for
safe and effective dosing in this patient?
A. Bioavailability (F)
B. Volume of Distribution (Vd)
C. Half-life (t½)
D. Protein Binding Percentage
Rationale: - answer-; C. Half-life (t½). In patients with significantly impaired renal
function, the half-life of renally excreted drugs like aminoglycosides (gentamicin)
is dramatically prolonged. Calculating the estimated half-life based on creatinine
clearance is essential to determine the dosing interval and prevent toxic
accumulation. While Vd (B) is used to calculate the loading dose, and protein
binding (D) can affect interactions, the critically altered parameter in renal failure
is the elimination half-life, which directly dictates the dosing frequency to avoid
,toxicity (nephrotoxicity, ototoxicity). Bioavailability (A) is less relevant for
intravenous dosing.
2. A patient stabilized on warfarin for atrial fibrillation begins taking phenytoin
for new-onset seizures. One week later, the patient's INR is subtherapeutic.
What is the MOST likely mechanism for this drug-drug interaction?
A. Phenytoin displaces warfarin from plasma protein binding sites.
B. Phenytoin inhibits the CYP2C9 metabolism of warfarin.
C. Phenytoin induces the CYP2C9 and CYP3A4 metabolism of warfarin.
D. Phenytoin reduces the absorption of warfarin in the GI tract.
Rationale: - answer-; C. Phenytoin induces the CYP2C9 and CYP3A4 metabolism
of warfarin. Phenytoin is a potent inducer of hepatic cytochrome P450 enzymes,
including CYP2C9 (the primary metabolizer of S-warfarin) and CYP3A4. This
increased enzymatic activity accelerates the metabolism and clearance of
warfarin, leading to a decreased anticoagulant effect and a subtherapeutic INR.
Answer A describes a protein-binding displacement interaction, which causes a
transient, sharp increase in free drug, not a sustained decrease. Answer B
describes an inhibitor, which would increase the INR. Answer D is not a
recognized significant interaction for these drugs.
Topic: Endocrine Pharmacology
3. A 55-year-old patient with Type 2 diabetes, hypertension, and established
atherosclerotic cardiovascular disease (ASCVD) presents with an A1C of 8.5% on
metformin 1000 mg BID. According to the current ADA/EASD consensus
guidelines, which of the following would be the MOST appropriate next
pharmacologic agent to add?
A. Glipizide (a sulfonylurea)
B. Sitagliptin (a DPP-4 inhibitor)
C. Empagliflozin (an SGLT2 inhibitor)
D. Pioglitazone (a thiazolidinedione)
Rationale: - answer-; C. Empagliflozin (an SGLT2 inhibitor). For patients with
Type 2 diabetes and established ASCVD (or heart failure, or CKD), the guidelines
strongly recommend an agent with proven cardiovascular benefit, such as an
SGLT2 inhibitor (empagliflozin, canagliflozin) or a GLP-1 receptor agonist with
proven benefit. Empagliflozin has robust data showing reduction in major adverse
,cardiovascular events (MACE) and hospitalization for heart failure. While all
options lower glucose, sulfonylureas (A) and DPP-4 inhibitors (B) are generally
considered glucose-centric with neutral CV effects. Pioglitazone (D) can increase
heart failure risk and is not a first-choice add-on in this specific clinical scenario.
4. A patient with primary hypothyroidism has been on a stable dose of
levothyroxine 112 mcg daily for one year with normal TSH. She now reports
starting calcium carbonate tablets for osteoporosis prevention. What is the
MOST appropriate clinical action?
A. Increase the levothyroxine dose by 25 mcg daily.
B. Check a TSH level in 6-8 weeks and counsel to separate administration times.
C. Switch to liothyronine (T3) therapy due to malabsorption.
D. No action is needed; there is no interaction.
Rationale: - answer-; B. Check a TSH level in 6-8 weeks and counsel to separate
administration times. Calcium carbonate (and other cations like iron, aluminum)
can bind to levothyroxine in the gut, significantly reducing its absorption. The
appropriate management is to instruct the patient to take levothyroxine on an
empty stomach (ideally 60 minutes before breakfast) and to take calcium
supplements (and other multivitamins) at a different time, such as with lunch or
dinner. A follow-up TSH is then required to ensure the patient's thyroid status
remains stable. Increasing the dose (A) preemptively is not appropriate. Switching
to T3 (C) is not standard management for this common interaction.
Topic: Cardiovascular & Renal Pharmacology
5. A 70-year-old man with heart failure with reduced ejection fraction (HFrEF, EF
28%), hypertension, and stage 3b CKD is on optimal therapy including lisinopril,
carvedilol, and furosemide. Despite this, he has persistent NYHA Class II
symptoms. Which of the following add-on therapies has been shown to reduce
cardiovascular mortality and HF hospitalizations in this population and is
appropriate given his renal function?
A. Digoxin
B. Hydralazine/isosorbide dinitrate
C. Spironolactone
D. Ivabradine
, Rationale: - answer-; C. Spironolactone (or its alternative eplerenone). In patients
with HFrEF (EF ≤35%) who remain symptomatic (NYHA Class II-IV) on an ACE-
I/ARB/ARNI and a beta-blocker, the addition of a mineralocorticoid receptor
antagonist (MRA) like spironolactone is a Class I recommendation based on the
RALES trial, showing significant reductions in mortality and hospitalization. It
requires monitoring of potassium and renal function but can be used with caution
in CKD. Digoxin (A) reduces hospitalizations but not mortality. Hydralazine/ISDN
(B) is specifically recommended for African American patients on optimal therapy.
Ivabradine (D) is for patients in sinus rhythm with a heart rate ≥70 bpm on max
beta-blocker therapy, and its benefit in concomitant significant CKD is less
defined.
Topic: Neurology/Psychiatry Pharmacology
6. A 45-year-old woman is diagnosed with major depressive disorder. She is
started on sertraline 50 mg daily. At her 2-week follow-up, she reports feeling
more anxious and having trouble sleeping. Her physical exam is normal. What is
the MOST appropriate next step?
A. Immediately discontinue sertraline due to risk of serotonin syndrome.
B. Add a benzodiazepine, such as lorazepam, for anxiety and insomnia.
C. Reassure the patient that these are common initial side effects and encourage
her to continue the medication.
D. Switch to a different antidepressant class, such as bupropion.
Rationale: - answer-; C. Reassure the patient that these are common initial side
effects and encourage her to continue the medication. Activation symptoms
(increased anxiety, agitation, insomnia) are a well-known, typically transient side
effect during the initial 1-3 weeks of SSRI therapy. The appropriate management
is education, reassurance, and support to persist, as the therapeutic
antidepressant effect often takes 4-8 weeks. Discontinuation (A) is premature.
Adding a benzodiazepine (B) may create a new problem of dependence and is not
first-line. Switching (D) may be considered if side effects are intolerable or persist,
but it is too early in treatment to make that decision.
7. A 28-year-old patient with moderate persistent asthma is prescribed a
combination inhaled corticosteroid/long-acting beta-agonist (ICS/LABA). The
patient uses a short-acting beta-agonist (SABA) albuterol inhaler 3-4 times per
